Mark E. Molitch
YOU?
Author Swipe
View article: 9191 Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience
9191 Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience Open
Disclosure: K.C. Yuen: Consulting Fee; Self; Novo Nordisk, Neurocrine, Crinetics, Recordati, Ascendis, Chiesi. Grant Recipient; Self; Ascendis, Corcept Therapeutics, Chiesi, Sparrow. Speaker; Self; Recordati, Novo Nordisk. W. Huang: Adviso…
View article: <b>Associations of kidney tubular biomarkers with incident macroalbuminuria and sustained low eGFR in DCCT/EDIC</b>
<b>Associations of kidney tubular biomarkers with incident macroalbuminuria and sustained low eGFR in DCCT/EDIC</b> Open
Objective: Tubulointerstitial injury contributes to diabetic kidney disease (DKD) progression. We tested tubular biomarker associations with DKD development in type 1 diabetes (T1D). Research Design and Methods: A case-cohort study examine…
View article: <b>Associations of kidney tubular biomarkers with incident macroalbuminuria and sustained low eGFR in DCCT/EDIC</b>
<b>Associations of kidney tubular biomarkers with incident macroalbuminuria and sustained low eGFR in DCCT/EDIC</b> Open
Objective: Tubulointerstitial injury contributes to diabetic kidney disease (DKD) progression. We tested tubular biomarker associations with DKD development in type 1 diabetes (T1D). Research Design and Methods: A case-cohort study examine…
View article: Peak insulin drip rate associated with decreased infections post‐solid organ transplant
Peak insulin drip rate associated with decreased infections post‐solid organ transplant Open
Infection and rejection outcomes were retrospectively analyzed in patients following liver transplant and separately following heart transplant with patients being stratified by their severity of immediate postoperative insulin resistance …
View article: SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry Open
Disclosure: E.B. Geer: Consulting Fee; Self; Amryt. Research Investigator; Self; Ionis, Amryt. W. Huang: Consulting Fee; Self; Amryt. Speaker; Self; Amryt. M.B. Gordon: Consulting Fee; Self; Recordati, Novo Nordisk. Research Investigator; …
View article: THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial Open
Disclosure: M. Fleseriu: Consulting Fee; Self; Amryt (fka Chiasma), Ipsen, Ionis Pharmaceuticals Inc., Recordati, Pfizer, Inc. Research Investigator; Self; Amryt(fka Chiasma), Crinetics, Ionis Pharmaceuticals Inc., Recordati. Other; Self; …
View article: MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly Open
Context The MPOWERED core trial (NCT02685709) and open-label extension (OLE) phase investigated long-term efficacy and safety of oral octreotide capsules (OOC) in patients with acromegaly. Core trial primary endpoint data demonstrated noni…
View article: CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes
CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes Open
Key Points We found that development of both albuminuria and reduced eGFR was associated with clinically significant cognitive decline, particularly in the psychomotor and mental efficiency domain. There was also a significant interaction …
View article: Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study
Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study Open
OBJECTIVE To describe the relationships between the cumulative incidences of long-term complications in individuals with type 1 diabetes (T1D) and assess whether observed associations are independent of age, duration of diabetes, and glyce…
View article: Relationships between the Cumulative Incidences of Long-Term Complications in Type 1 Diabetes Mellitus: the DCCT/EDIC Study
Relationships between the Cumulative Incidences of Long-Term Complications in Type 1 Diabetes Mellitus: the DCCT/EDIC Study Open
Objective To describe the relationships between the cumulative incidences of long-term complications in individuals with type 1 diabetes (T1D), and assess whether observed associations are independent of age, duration of diabetes, and gl…
View article: Relationships between the Cumulative Incidences of Long-Term Complications in Type 1 Diabetes Mellitus: the DCCT/EDIC Study
Relationships between the Cumulative Incidences of Long-Term Complications in Type 1 Diabetes Mellitus: the DCCT/EDIC Study Open
Objective To describe the relationships between the cumulative incidences of long-term complications in individuals with type 1 diabetes (T1D), and assess whether observed associations are independent of age, duration of diabetes, and gl…
View article: Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes Open
OBJECTIVE Kidney disease screening recommendations include annual urine testing for albuminuria after 5 years’ duration of type 1 diabetes. We aimed to determine a simple, risk factor–based screening schedule that optimizes early detection…
View article: Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes Open
Background. Kidney disease screening recommendations include annual urine testing for albuminuria after five years duration of type 1 diabetes. We aimed to determine a simple, risk factor-based screening schedule that optimizes early det…
View article: Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes Open
Background. Kidney disease screening recommendations include annual urine testing for albuminuria after five years duration of type 1 diabetes. We aimed to determine a simple, risk factor-based screening schedule that optimizes early det…
View article: RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase Open
Background Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octre…
View article: PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial Open
Background Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous pha…
View article: LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly Open
Background Oral octreotide capsules (OOC) are an approved treatment option in the United States for patients with acromegaly who have previously responded to injectable somatostatin receptor ligands (iSRLs). Safety and efficacy of OOC was …
View article: Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study
Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study Open
OBJECTIVE To determine long-term outcomes for islet-alone and islet-after-kidney transplantation in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia. RESEARCH DESIGN AND METHODS This was a prospective intervent…
View article: Durable biochemical response and safety with oral octreotide capsules in acromegaly
Durable biochemical response and safety with oral octreotide capsules in acromegaly Open
Objective The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the long-term durability of therapeutic response. D…
View article: Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy
Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy Open
In patients with T1D and microalbuminuria, uAOG is increased and varies with gender and the type of insulin therapy independently of AER. This suggests that AOG production is increased in females and it is decreased by intensive insulin th…
View article: Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes Open
Background: Rapid loss of estimated Glomerular Filtration Rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 di…
View article: Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes Open
Background: Rapid loss of estimated Glomerular Filtration Rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 di…
View article: Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes Open
OBJECTIVE Rapid loss of estimated glomerular filtration rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 diab…